15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Theravance Biopharma Inc, 0 rate it Buy or better, 6 sit at Hold, and 0 rate it Sell or worse, a hold consensus. Targets span $15.00 to $27.00, a moderate spread. The average target of $19.40 sits 14% above the current $17.06. The rating mix has stayed broadly stable, with Buy-side ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $1.27 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Hold
Strong Buy00%
Buy00%
Hold6100%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Theravance Biopharma Inc.
As of Sep, 0 of 6 firms rate TBPH a Buy (6 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TBPH EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.08 – $-0.08 · 1 analysts · -236% YoY
Next period, 1 analysts expect Theravance Biopharma Inc to earn $-0.08 a share (range $-0.08 – $-0.08), versus $0.06 a year earlier. Full-year consensus is $0.21, growing to $1.27 the year after.
REVENUE · NEXT QUARTER
$22.6M
Range $20.7M – $24.1M · 1 analysts · -51% YoY
Revenue is expected to reach $22.6M (range $20.7M – $24.1M), -50.7% year-over-year. Full-year consensus is $90.7M, rising to $97.4M next year.
Top analysts covering Theravance Biopharma Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TBPH.
#1
Mayank Mamtani
B. Riley Securities · Rank #41
Hold
$17.00-0.4% to target
Overall win rate
50%
+ Follow
#2
Douglas Tsao
HC Wainwright & Co. · Rank #248
Hold
$17.00-0.4% to target
Overall win rate
35%
+ Follow
#3
Julian Harrison
BTIG
Hold
No targeton TBPH
Coverage
—
+ Follow
#4
TA
Trevor Allred
Oppenheimer
Hold
$13.67-19.9% to target
Coverage
—
+ Follow
#5
DC
Debanjana Chatterjee
Jones Trading
Hold
No targeton TBPH
Coverage
—
+ Follow
TBPH stock forecast FAQ
What is TBPH's average 12-month price target?+
The 3 analysts with a live target average $19.40 for Theravance Biopharma Inc over the next 12 months, ranging from a $27.00 high to a $15.00 low.
Is TBPH stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 6 analyst ratings, 0 are Buy or Strong Buy, 6 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TBPH?+
The Street-high target is $27.00, and the Street-low is $15.00 (TD Cowen). The average of all 3 active targets is $19.40.
How many Wall Street analysts cover TBPH?+
6 analysts have an active rating on Theravance Biopharma Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering TBPH?+
Among analysts who currently cover TBPH, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #41). Their current call is Hold with a $17.00 target.
What is Theravance Biopharma Inc's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.08 – $-0.08) across 1 analysts. Full-year EPS is projected at $0.21, rising to $1.27 the following year.
How much revenue is Theravance Biopharma Inc expected to report next quarter?+
Consensus revenue is $22.6M (range $20.7M – $24.1M). Full-year revenue is projected at $90.7M, growing to $97.4M next year.
Have analysts been upgrading or downgrading TBPH lately?+
As of Sep, 0 of 6 firms rate TBPH a Buy (6 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TBPH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
